9 results
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Oral anticoagulant ... Clotmaster #VTE #DOAC ... #Anticoagulation ... #Dabigatran #Apixaban ... #Rivaroxaban #Edoxaban
Oral Anticoagulation Management Cheat Sheet: Warfarin, Apixaban, Dabigatran, Rivaroxaban
 - Mechanism of Action
 - Routine Blood
Oral Anticoagulation ... Management Cheat ... Sheet: Warfarin, Apixaban ... , Dabigatran, Rivaroxaban ... Anticoagulant #DOAC
Heparin, Fondaparinux, and Novel Oral Anticoagulants - Pathophysiology

Anticoagulation with parenteral (intravenous or subcutaneous) and oral anticoagulants
Pathophysiology Anticoagulation ... warfarin) for chronic anticoagulation ... accelerates the bridging ... Heparins #LMWH #UFH #DOAC ... #Dabigatran #Apixaban
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
, edoxaban and rivaroxaban ... direct-acting oral ... randomized controlled trial ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology
Perioperative Management of DOACs
Problem:
 ✖ Each year approximately 250,000 patients on chronic anticoagulation in North America
Perioperative Management ... patients on chronic anticoagulation ... direct acting oral ... inhibitor) • Apixaban ... , Edoxaban, Rivaroxaban
Cardiac Valve Replacement - Anticoagulation INR Targets and Antiplatelet by Valve Type

Bioprosthetic valves require at least
utilize direct oral ... anticoagulants (DOACs ... patients with chronic atrial ... #Management #Cardiology ... #INR #Target #DOAC
Atrial Fibrillation (A-Fib) Summary

Symptoms:
• Palpitations, light-headedness, dizziness, dyspnea, exercise intolerance, chest pain, near-syncope, syncope.

Why?
Cardiac:
	• Valvular heart
typically needed • DOACs ... Xa inhibitors (rivaroxaban ... , apixaban, edoxaban ... Fibrillation #AFib #diagnosis ... #management #cardiology
Antiphospholipid Syndrome (APS)
APS is a rare autoimmune disorder characterized by recurring blood clots resulting from antibodies
Treatment (EULAR Guidelines ... ): • Anticoagulation ... target to 3-4 • DOACs ... #management #anticoagulation ... #guidelines
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Differential Diagnosis ... Avoid Warfarin and DOAC ... suggest prophylactic anticoagulation ... e.g., <50%), ESC guidelines ... Serial TTE and close